How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

Table 3

Eligibility criteria for the CANVAS program (canagliflozin) and number of patients in the SIDIAP database that would have met criteria for enrolment.

Eligibility criteria in the CANVAS program	Potentially eligible patients from the SIDIAP database ()
Inclusion criteria	In PP, (%)	In SP, (%)
Age:
≥50 years in PP	349,896 (93.8)	—
≥30 years in SP	—	372,764 (99.9)
Primary prevention cohort
≥50 years and ≥2 CVRF: (i) T2D duration ≥10 years; (ii) Hypertension; (iii) Current smoker; (iv) Micro- or macroalbuminuria; (v) (1 mmol/l)	189,969 (50.9)	—
Secondary prevention cohort
≥30 years and history of CV events (CHD, angina, MI, stroke, and PAD)	—	86,531 (23.2)
HbA1c: 7.0%-10.5%	83,537 (22.4)	34,320 (9.2)
Main exclusion criteria	In PP, (%)	In SP, (%)
	4731 (1.27)	2575 (0.69)
Total eligible in PP and SP, (%)	78,806 (21.1)	31,745 (8.5)
Total eligible, (%)	110,551 (29.6)

CHD: coronary heart disease; CV: cardiovascular; CVRF: cardiovascular risk factors; eGFR: estimated glomerular filtration rate; MI: myocardial infarction; PP: primary cardiovascular prevention; SP: secondary cardiovascular prevention; PAD: peripheral artery disease; T2D: type 2 diabetes; HbA1c: glycated haemoglobin; HDLc: high-density lipoprotein cholesterol. All the percentages refer to the proportion from the total number of eligible subjects of the SIDIAP database ().